07.16.21
Headquarters: Tokyo, Japan
twitter.com/AstellasUS
www.astellas.com
Headcount: 15,883
Year Established: 2003
Revenues: $11,338 (-4%)
Net Income: $1,905 (-4%)
R&D: $2,037 (0%)
TOP SELLING DRUGS
Astella’s revenue in fiscal year 2020 decreased 4% to $11.3 billion, mainly due to the loss of market exclusivity of Vesicare for the treatment of overactive bladder in Europe, and the termination of sales agreements for Symbicort for asthma, human vaccines of KM Biologics Co., Ltd., Micardis family for the treatment of hypertension, and Celecox for the treatment of inflammation and pain in Japan.
Despite the challenges of 2020, sales of main products XTANDI for the treatment of prostate cancer and XOSPATA for the treatment of acute myeloid leukemia continued to grow. In addition, growth of the co-promotion revenue of PADCEV for the treatment of urothelial cancer contributed to revenue. Moreover, sales of Betanis / Myrbetriq / BETMIGA for the treatment of OAB showed steady progress, and new product groups in Japan achieved sales growth, including those of EVENITY for the treatment of osteoporosis, Suglat and SUJANU Combination Tablets for the treatment of diabetes mellitus.
In pipeline news, the company submitted an application in the U.S. in December 2020 for immunosuppressant agent Prograf for an additional indication of prevention of rejection in lung transplantation. In March 2021, the company obtained the approval of a new oral extended-release formulation and existing tablets for the additional indication of neurogenic detrusor overactivity in children aged three years and older for the OAB treatment Myrbetriq in the U.S.
In 2018, Astellas adopted an approach called “Focus Area Approach” as its research and development strategy. As of March 2021, it has selected four Primary Focuses: "Blindness & Regeneration," "Mitochondria Biology," "Genetic Regulation," and "Immuno-Oncology."
In January 2020, Astellas acquired Audentes Therapeutics, Inc, and gained capabilities for gene therapy, including technology platforms and manufacturing capabilities to develop new drug candidates into clinical stage. By obtaining these assets, Astellas has made a significant first step toward becoming a front runner in this area. In April 2021, it reorganized the Audentes Division to establish a research and manufacturing division, a development division, and a commercial division that will specialize in the area of gene therapy.
In September 2020, the company initiated a joint research collaboration with the University of Pittsburgh in gene therapy using Adeno-associated viruses to create development candidates for the treatment of dry age-related macular degeneration. Also in September, the company signed an agreement with the University of Tokyo’s Center of Innovation on collaborative efforts to create innovative new drugs and medical solutions.
In December 2020, Astellas entered into an exclusive worldwide license agreement with KaliVir Immunotherapeutics LLC for the collaboration, development and commercialization of VET2-L2, an intravenously administered oncolytic virus, as well as a second, follow-on development candidate.
In January 2021, the Kyushu Distribution Center, the company’s fourth distribution base in Japan, began operations in Kitakyushu City. Furthermore, Astellas began construction on a new sterile drug production line in the Yaizu Technology Center of Astellas Pharma Tech Co., Ltd., a manufacturing subsidiary of the company.
twitter.com/AstellasUS
www.astellas.com
Headcount: 15,883
Year Established: 2003
Revenues: $11,338 (-4%)
Net Income: $1,905 (-4%)
R&D: $2,037 (0%)
TOP SELLING DRUGS
Drug | Indication | 2020 Sales | (+/-%) |
Xtandi | Prostate Cancer | $4,160 | 14% |
Prograf | Liver transplantation | $1,660 | -5% |
Betanis/Myrbetriq/Betmiga | Overactive bladder | $1,490 | 1% |
Vesicare | Overactive bladder | $290 | -29% |
Mycamine | Candidiasis | $230 | -27% |
Xospata | Acute myeloid leukemia | $220 | 67% |
Padcev | Urothelial cancer | $120 | +>100% |
Eligard | Prostate Cancer | $87 | -33% |
Evrenzo | Renal anemia | $10 | +>100% |
Astella’s revenue in fiscal year 2020 decreased 4% to $11.3 billion, mainly due to the loss of market exclusivity of Vesicare for the treatment of overactive bladder in Europe, and the termination of sales agreements for Symbicort for asthma, human vaccines of KM Biologics Co., Ltd., Micardis family for the treatment of hypertension, and Celecox for the treatment of inflammation and pain in Japan.
Despite the challenges of 2020, sales of main products XTANDI for the treatment of prostate cancer and XOSPATA for the treatment of acute myeloid leukemia continued to grow. In addition, growth of the co-promotion revenue of PADCEV for the treatment of urothelial cancer contributed to revenue. Moreover, sales of Betanis / Myrbetriq / BETMIGA for the treatment of OAB showed steady progress, and new product groups in Japan achieved sales growth, including those of EVENITY for the treatment of osteoporosis, Suglat and SUJANU Combination Tablets for the treatment of diabetes mellitus.
In pipeline news, the company submitted an application in the U.S. in December 2020 for immunosuppressant agent Prograf for an additional indication of prevention of rejection in lung transplantation. In March 2021, the company obtained the approval of a new oral extended-release formulation and existing tablets for the additional indication of neurogenic detrusor overactivity in children aged three years and older for the OAB treatment Myrbetriq in the U.S.
In 2018, Astellas adopted an approach called “Focus Area Approach” as its research and development strategy. As of March 2021, it has selected four Primary Focuses: "Blindness & Regeneration," "Mitochondria Biology," "Genetic Regulation," and "Immuno-Oncology."
In January 2020, Astellas acquired Audentes Therapeutics, Inc, and gained capabilities for gene therapy, including technology platforms and manufacturing capabilities to develop new drug candidates into clinical stage. By obtaining these assets, Astellas has made a significant first step toward becoming a front runner in this area. In April 2021, it reorganized the Audentes Division to establish a research and manufacturing division, a development division, and a commercial division that will specialize in the area of gene therapy.
In September 2020, the company initiated a joint research collaboration with the University of Pittsburgh in gene therapy using Adeno-associated viruses to create development candidates for the treatment of dry age-related macular degeneration. Also in September, the company signed an agreement with the University of Tokyo’s Center of Innovation on collaborative efforts to create innovative new drugs and medical solutions.
In December 2020, Astellas entered into an exclusive worldwide license agreement with KaliVir Immunotherapeutics LLC for the collaboration, development and commercialization of VET2-L2, an intravenously administered oncolytic virus, as well as a second, follow-on development candidate.
In January 2021, the Kyushu Distribution Center, the company’s fourth distribution base in Japan, began operations in Kitakyushu City. Furthermore, Astellas began construction on a new sterile drug production line in the Yaizu Technology Center of Astellas Pharma Tech Co., Ltd., a manufacturing subsidiary of the company.